Literature DB >> 9371932

The measurement of ambulatory impairment in multiple sclerosis.

S R Schwid1, A D Goodman, D H Mattson, C Mihai, K M Donohoe, M D Petrie, E A Scheid, J T Dudman, M P McDermott.   

Abstract

The objective of this study was to examine the relationships between continuous measures of ambulatory impairment in MS patients and their ordinal counterparts. Much of the disability caused by MS is due to ambulatory impairment. The Expanded Disability Severity Scale (EDSS) and the Ambulation Index (AI) are ordinal measures of MS severity based largely on the maximal distance subjects can walk (Dmax) and the time to walk 8 m (T8), respectively. At EDSS levels 6.0 to 7.0 and AI levels 3 to 6, scores are defined more by the use of ambulatory aids, rather than by Dmax or T8. We determined Dmax (up to 500 m), T8, the EDSS score, and the AI in 237 ambulatory MS patients. The maximal distance subjects could walk and T8 were strongly related to their ordinal counterparts (Spearman r = 0.65 and 0.91, respectively), but the continuous measures showed considerable variability within EDSS and AI levels that the ordinal scales did not reflect. Most of the variability occurred at EDSS levels 6.0 to 7.0 and AI levels 3 to 6. Because the use of an aid did not clearly predict Dmax or T8, many patients in these ranges had better ambulatory function based on the continuous measures than those with less disability according to the ordinal scales. We found that Dmax and T8 provide more precise information about ambulatory impairment in MS than do the EDSS and AI, allowing better discrimination of differences between patients and potentially greater sensitivity to detect therapeutic effects in clinical trials.

Entities:  

Mesh:

Year:  1997        PMID: 9371932     DOI: 10.1212/wnl.49.5.1419

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

2.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 3.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

4.  A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Randall T Schapiro; Michael Klingler; Ron Cohen; Andrew R Blight
Journal:  Int J MS Care       Date:  2014

5.  Quantitative measures detect sensory and motor impairments in multiple sclerosis.

Authors:  Scott D Newsome; Joseph I Wang; Jonathan Y Kang; Peter A Calabresi; Kathleen M Zackowski
Journal:  J Neurol Sci       Date:  2011-04-01       Impact factor: 3.181

6.  Validity of the Verbal Concept Attainment Test in multiple sclerosis.

Authors:  Ryan Mulligan; Michael R Basso; Lily Lau; Bradley Reynolds; Douglas M Whiteside; Dennis Combs; Robert A Bornstein
Journal:  J Clin Exp Neuropsychol       Date:  2019-01-14       Impact factor: 2.475

7.  Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord.

Authors:  Kathleen M Zackowski; Seth A Smith; Daniel S Reich; Eliza Gordon-Lipkin; BettyAnn A Chodkowski; Divya R Sambandan; Michael Shteyman; Amy J Bastian; Peter C van Zijl; Peter A Calabresi
Journal:  Brain       Date:  2009-03-18       Impact factor: 13.501

8.  Walking impairment in patients with multiple sclerosis: exercise training as a treatment option.

Authors:  Robert W Motl; Myla D Goldman; Ralph H B Benedict
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-16       Impact factor: 2.570

9.  Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

Authors:  Richard A Rudick; Jar-Chi Lee; Kunio Nakamura; Elizabeth Fisher
Journal:  J Neurol Sci       Date:  2008-12-19       Impact factor: 3.181

10.  Comparison of speeds used for the 15.2-meter and 6-minute walks over the year after an incomplete spinal cord injury: the SCILT Trial.

Authors:  H Barbeau; R Elashoff; D Deforge; J Ditunno; M Saulino; B H Dobkin
Journal:  Neurorehabil Neural Repair       Date:  2007-03-16       Impact factor: 3.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.